NKTR
Nektar soared today on cancer drug data–but remember that new opioid? That’s why I say hold even after this run
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Nektar soars–again–on oncology drug data
Shares of Nektar Therapeutics (NKTR) are up another 16% this morning to $37.89 as of noon New York time on data presented this weekend at the annual meeting of the Society for Immunotherapy of Cancer from an early trial of Nektar's NKTR-214. The data looked at the...
Nektar rockets ahead, options in my Volatility Portfolio head for orbit
On the evening of October 31 I wrote that a decision onwhat to do with the Netkar Therapeutics options (NKTR180119C00022000)--the January 19, 2018 call at $22--that I added to my Volatility Portfolio back on May 16, 2017 at a price of $2.64 (the closing options price...
What to do with those Nektar options ahead of November 2 earnings?
This is a tough one. A very tough one. I added Netkar options (NKTR180119C00022000)--the January 19, 2018 call at $22--to my volatility portfolio back on May 16, 2017 at a price of $2.64 (the closing options price on that day.) Â Today, using the last price again on...
Nervous market has been hard on Nektar; hold options in my Volatility Portfolio for September news (and beyond)
Biotechs--and indeed any high price-to-earnings stocks perceived as risky--have taken more than their share of punishment in the nervous sell off of the last few weeks. Nektar Therapeutics (NKTR), for example, closed yesterday August 21 at $17.79. That's down from...
The market’s doing it again–forgetting that earnings don’t matter with immature biotech stocks such as Nektar
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Rebuying Nektar Therapeutics in my Volatility Portfolio–this time using options
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Selling Nektar out of my Volatility Portfolio after near 40% pop today
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Market moves to risk off just before start of biotech conference season, opening for short term biotech trades? Adding Nektar to my Volatility Portfolio
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...Jim’s Stock Alerts
Download Jim’s eBook for Free
